<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624255</url>
  </required_header>
  <id_info>
    <org_study_id>2022/701</org_study_id>
    <nct_id>NCT05624255</nct_id>
  </id_info>
  <brief_title>Correlating the Measure of Retinal Vascular Density Through Angio-OCT With Calcium Score</brief_title>
  <acronym>ANOSCA</acronym>
  <official_title>Correlating the Measure of Retinal Vascular Density Through Angio-OCT With Calcium Score</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent case-control studies have proven that the retinal vascularization mirrors the cardiac&#xD;
      vascularization: more the coronary network is altered, more the density of retinal vessels is&#xD;
      reduced. No studies have yet been realised in primary prevention. This study aims to&#xD;
      demonstrate a link between the density of the retinal vascularization and the calcium score,&#xD;
      which is currently the gold standard for the classification of cardiovascular risk in primary&#xD;
      prevention. Thus, a simple image of the retinal vascularization could predict the&#xD;
      cardiovascular risk of a patient. OCT angiography would become a major aid in the&#xD;
      classification of cardiovascular risk in asymptomatic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2022</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between retinal vascular density and calcium score</measure>
    <time_frame>Day 1</time_frame>
    <description>Comparison between values of calcium score and presence of vascular abnormalities in retina.&#xD;
Calcium is scored as follows:&#xD;
Coronary Artery Calcium [CAC] = 0 : very low risk&#xD;
CAC = [1-100[ : low risk&#xD;
CAC = [100-400[ : moderate risque&#xD;
CAC = [400-1000[ : high risk&#xD;
CAC = &gt; 1000 : very high risk</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiovascular Abnormalities</condition>
  <condition>Vascular Diseases</condition>
  <condition>Retinal Vascular</condition>
  <arm_group>
    <arm_group_label>ophthalmology consultation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients eligible to calcium score will be offered an ophthalmologic consultation including Angio-Optical Coherence Tomography [OCT]</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ophthalmologic consultation</intervention_name>
    <description>Complete ophthalmologic examination including angio-OCT</description>
    <arm_group_label>ophthalmology consultation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients eligible for a calcium score as part of their standard treatment and&#xD;
             volunteers for an ophthalmologic consultation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valentin WETZEL, Int</last_name>
    <phone>0033381664417</phone>
    <email>wetzel.valentin70@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Sophie GAUTHIER, MD PhD</last_name>
    <email>asgauthier@chu-besancon.fr</email>
  </overall_contact_backup>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 21, 2022</last_update_submitted>
  <last_update_submitted_qc>November 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Cardiovascular Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

